Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation Reply

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMARQUES, Igor Denizarde Bacelar
dc.contributor.authorELIAS, Rosilene Motta
dc.contributor.authorMOYSES, Rosa Maria Affonso
dc.contributor.authorDAVID-NETO, Elias
dc.date.accessioned2019-06-26T17:34:21Z
dc.date.available2019-06-26T17:34:21Z
dc.date.issued2019
dc.description.indexMEDLINEeng
dc.identifier.citationJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, v.30, n.5, p.906-906, 2019
dc.identifier.doi10.1681/ASN.2019020124
dc.identifier.eissn1533-3450
dc.identifier.issn1046-6673
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/32562
dc.language.isoeng
dc.publisherAMER SOC NEPHROLOGYeng
dc.relation.ispartofJournal of the American Society of Nephrology
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright AMER SOC NEPHROLOGYeng
dc.subjectkidney diseaseeng
dc.subjectrenal osteodystrophyeng
dc.subjectzoledronic acideng
dc.subject.wosUrology & Nephrologyeng
dc.titleBiphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation Replyeng
dc.typearticleeng
dc.type.categorylettereng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcIGOR DENIZARDE BACELAR MARQUES
hcfmusp.contributor.author-fmusphcROSILENE MOTTA ELIAS
hcfmusp.contributor.author-fmusphcROSA MARIA AFFONSO MOYSES
hcfmusp.contributor.author-fmusphcELIAS DAVID NETO
hcfmusp.description.beginpage906
hcfmusp.description.endpage906
hcfmusp.description.issue5
hcfmusp.description.volume30
hcfmusp.origemWOS
hcfmusp.origem.pubmed30910936
hcfmusp.origem.scopus2-s2.0-85065509742
hcfmusp.origem.wosWOS:000467401000015
hcfmusp.publisher.cityWASHINGTONeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceMarques IDB, 2019, J AM SOC NEPHROL, V30, P355, DOI 10.1681/ASN.2018060656eng
hcfmusp.relation.referencede Carvalho KSB, 2019, OSTEOPOROSIS INT, V30, P1015, DOI 10.1007/s00198-019-04864-4eng
hcfmusp.relation.referenceHart A, 2018, AM J TRANSPLANT, V18, P18, DOI 10.1111/ajt.14557eng
hcfmusp.relation.referenceSegaud N, 2018, OSTEOPOROSIS INT, V29, P1165, DOI 10.1007/s00198-018-4383-2eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationb3c6911f-2549-4aa6-a920-a128e42f6482
relation.isAuthorOfPublication96f51de1-5516-4c3f-8bbe-e187ad50e121
relation.isAuthorOfPublication75bfa547-8f40-42b9-9d98-3bafa53bb29b
relation.isAuthorOfPublicationbc30aed5-42c2-4d19-8ad0-bd7f8be7faef
relation.isAuthorOfPublication.latestForDiscoveryb3c6911f-2549-4aa6-a920-a128e42f6482
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MARQUES_Biphosphonate_Therapy_Risk_of_Fracture_and_Sites_of_2019.PDF
Tamanho:
416.24 KB
Formato:
Adobe Portable Document Format